Filing Flows › Arbutus Biopharma (ABUS) › Non-cash royalty revenue revenue
Arbutus Biopharma (ABUS) Non-cash royalty revenue revenue by quarter
Arbutus Biopharma's Non-cash royalty revenue revenue was $180K in Q2 2026 (second quarter 2026), -0.6% from Q1 2026. Over the last 7 quarters it ranged from $180K (Q2 2026) to $526K (Q2 2025).
| Quarter | Non-cash royalty revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $180K | -0.6% | -66% |
| Q1 2026 | $181K | -30% | -60% |
| Q4 2025 | $259K | +4% | -50% |
| Q3 2025 | $249K | -53% | — |
| Q2 2025 | $526K | +17% | — |
| Q1 2025 | $448K | -13% | — |
| Q4 2024 | $516K | — | — |
Q2 2026 at a glance
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arbutus Biopharma's Non-cash royalty revenue revenue?
Arbutus Biopharma's Non-cash royalty revenue revenue was $180K in Q2 2026 (second quarter 2026), -0.6% from Q1 2026.
How has Arbutus Biopharma's Non-cash royalty revenue revenue changed?
Over the last 7 quarters it ranged from $180K (Q2 2026) to $526K (Q2 2025).